3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
NIH
2
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
330
Breast Neoplasms
185
Lung Neoplasms
177
Ovarian Neoplasms
156
Triple Negative Breast Neoplasms
88
Fallopian Tube Neoplasms
75
Squamous Cell Carcinoma of Head and Neck
74
Small Cell Lung Carcinoma
67
Esophageal Neoplasms
55
Neoplasms
49
Head and Neck Neoplasms
47
Carcinoma, Ovarian Epithelial
44
Uterine Cervical Neoplasms
36
Esophageal Squamous Cell Carcinoma
36
Endometrial Neoplasms
35
Prostatic Neoplasms
33
Neoplasm Metastasis
32
Lymphoma, Large B-Cell, Diffuse
32
Recurrence
31
Adenocarcinoma of Lung
31
Lymphoma
30
Brain Neoplasms
29
Neuroblastoma
24
Central Nervous System Neoplasms
24
Retinoblastoma
23
Lymphoma, Non-Hodgkin
23
Carcinoma, Squamous Cell
23
Hodgkin Disease
20
Testicular Neoplasms
19
Urinary Bladder Neoplasms
16
Interventions
Paclitaxel
7
Doxorubicin
5
pembrolizumab
4
pazopanib
4
Gemcitabine
4
Bevacizumab
4
durvalumab
3
Radiotherapy
3
Propranolol
3
Docetaxel
3
regorafenib
2
cemiplimab
2
Surveys and Questionnaires
2
Sunitinib
2
Standard of Care
2
Nivolumab
2
Ifosfamide
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
tremelimumab
1
trebananib
1
trastuzumab duocarmazine
1
talimogene laherparepvec
1
talazoparib
1
spartalizumab
1
sintilimab
1
selinexor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hemangiosarcoma
×
Carboplatin
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled